What's Happening?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results for their next-generation selective RET inhibitor, lunbotinib fumarate, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The
study focused on patients with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The trial included 71 pre-treated patients and 92 treatment-naïve patients, showing an objective response rate of 81.3% in treatment-naïve and 87.1% in pre-treated patients. The drug demonstrated significant efficacy, particularly in patients with central nervous system metastases, achieving a 30% intracranial complete response rate. Lunbotinib fumarate was well tolerated, with minimal treatment-related adverse events leading to discontinuation.
Why It's Important?
The results of this study are significant as they highlight the potential of lunbotinib fumarate to become a vital treatment option for patients with RET fusion-positive NSCLC, a condition with limited effective therapies. The high response rates and manageable safety profile suggest that this drug could improve outcomes for patients, particularly those with central nervous system metastases. This development is crucial for the U.S. healthcare sector, as it may lead to new treatment protocols and improve survival rates for a challenging cancer type. The acceptance of the New Drug Application by China's National Medical Products Administration also indicates potential for global market expansion.
What's Next?
Following the presentation of these results, the next steps involve the continued evaluation of lunbotinib fumarate in ongoing clinical trials. The drug is currently under review by the National Medical Products Administration in China, and further studies are being conducted in the U.S., U.K., Europe, and the UAE. These trials will assess the drug as a monotherapy and in combination with chemotherapy. If approved, lunbotinib fumarate could become a standard treatment for RET fusion-positive NSCLC, influencing treatment guidelines and patient care strategies worldwide.
